Icons / Logo / Facebook Created with Sketch. Icons / Logo / Google Created with Sketch. Icons / Logo / ORCID Created with Sketch. Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Su Jong Yu
Seoul National University
190Publications
19H-index
1,339Citations
Publications 190
Newest
Published on Dec 1, 2019in BMC Cancer 2.93
Jun Sik Yoon (Inje University), Byeong Geun Song1
Estimated H-index: 1
(SMC: Samsung Medical Center)
+ 10 AuthorsDong Hyun Sinn19
Estimated H-index: 19
(SMC: Samsung Medical Center)
Background Several randomized controlled trials have shown that adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) after curative treatment for hepatocellular carcinoma (HCC). We investigated the efficacy of adjuvant immunotherapy with activated CIK cells in real-world clinical practice.
Published in Scientific Reports 4.01
Yun Bin Lee8
Estimated H-index: 8
(SNU: Seoul National University),
Joon Yeul Nam4
Estimated H-index: 4
(SNU: Seoul National University)
+ -3 AuthorsDeok Hee Lee51
Estimated H-index: 51
(SNU: Seoul National University)
Published on May 3, 2019in Gut and Liver 2.97
Young Youn Cho9
Estimated H-index: 9
(CAU: Chung-Ang University),
Young Jun Chang19
Estimated H-index: 19
(SNU: Seoul National University)
+ 6 AuthorsYoon Jun Kim36
Estimated H-index: 36
(SNU: Seoul National University)
Published on Jul 17, 2019in European Journal of Neurology 4.39
Su-Min Jeong1
Estimated H-index: 1
(Seoul National University Hospital),
Hyung-Min Kwon17
Estimated H-index: 17
(Seoul National University Hospital)
+ 5 AuthorsJonghanne Park15
Estimated H-index: 15
(SNU: Seoul National University)
Published on Jun 4, 2019in Liver International 5.54
Sungwon Chung (SNU: Seoul National University), Jeong-Hoon Lee22
Estimated H-index: 22
(SNU: Seoul National University)
+ 11 AuthorsYun Bin Lee8
Estimated H-index: 8
(SNU: Seoul National University)
Published on Jun 7, 2019in European Radiology 3.96
Jae Seok Bae2
Estimated H-index: 2
(Seoul National University Hospital),
Dong Ho Lee3
Estimated H-index: 3
(Seoul National University Hospital)
+ 7 AuthorsByung Ihn Choi66
Estimated H-index: 66
(CAU: Chung-Ang University)
Objectives To evaluate the diagnostic performance of attenuation imaging (ATI) in the detection of hepatic steatosis compared with a histopathology gold standard.
Published on Jun 1, 2019in European Radiology 3.96
Deok Hee Lee51
Estimated H-index: 51
(Seoul National University Hospital),
Dong Ho Lee3
Estimated H-index: 3
(Seoul National University Hospital)
+ 9 AuthorsYoon Jun Kim11
Estimated H-index: 11
(Seoul National University Hospital)
Objective This study was conducted in order to evaluate whether the presence of nonhypervascular hepatobiliary phase (HBP) hypointense nodules can help determine the treatment method for single nodular hepatocellular carcinoma (HCC) ≤ 3 cm.
Published on Jun 1, 2019in Journal of Hepatology 18.95
Eun-Sook Park10
Estimated H-index: 10
(Konkuk University),
Ah Ram Lee4
Estimated H-index: 4
(Konkuk University)
+ 23 AuthorsHong Seok Kang6
Estimated H-index: 6
(Konkuk University)
Background & Aims Tenofovir disoproxil fumarate (TDF) is one the most potent nucleot(s)ide analogues for treating chronic hepatitis B virus (HBV) infection. Phenotypic resistance caused by genotypic resistance to TDF has not been reported. This study aimed to characterize HBV mutations that confer tenofovir resistance. Methods Two patients with viral breakthrough during treatment with TDF-containing regimens were prospectively enrolled. The gene encoding HBV reverse transcriptase was sequenced. ...
Published on Dec 7, 2018in Investigational New Drugs 2.66
Changhoon Yoo16
Estimated H-index: 16
(UOU: University of Ulsan),
Joong Won Park5
Estimated H-index: 5
+ 6 AuthorsDo Hoon Lim44
Estimated H-index: 44
(SKKU: Sungkyunkwan University)
Background The pivotal RESORCE trial showed that regorafenib was effective as second-line therapy for patients with advanced HCC who progressed on first-line sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice. Methods Between April 2017 and August 2017, the Named Patient Program (NPP) was activated to provide controlled, pre-approval access of regorafenib in Korea. This analysis is a multicenter retrospective study of patients wh...
12345678910